Brukinsa (zanubrutinib) — Medica
Follicular lymphoma
Initial criteria
- Patient is age ≥ 18 years
- Patient has tried at least two other systemic regimens
- Medication will be used in combination with Gazyva (obinutuzumab intravenous infusion)
Approval duration
1 year